Acurx报告了与莱顿大学医学中心合作使用伊贝扎普尔司他的研究结果

Mechanistic findings explain ibezapolstat's properties of lacking cross resistance with other antibiotics and not fostering the emergence of Enterococcus, including vancomycin-resistant strains, a unique differentiation among anti-CDI antibiotics. Planning continues to prepare to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection (CDI)